By Suherman Candra Maholtra 
The landscape of preventative dermatology is undergoing a significant shift as new research confirms the efficacy of nicotinamide, a specific form of vitamin B3, in reducing the incidence of non-melanoma skin cancers. While dermatologists have tentatively recommended the supplement for nearly a decade, a massive new study utilizing data from the United States Department of Veterans Affairs (VA) has provided the most robust evidence to date. The findings suggest that timing is a critical factor in the supplement’s success, with the greatest benefits realized when treatment begins immediately following a patient’s first skin cancer diagnosis.
A New Milestone in Preventative Dermatology
For years, the clinical community relied on a foundational study from 2015 to guide recommendations for patients at high risk for skin cancer. That initial trial, though influential, was limited in scope, involving fewer than 400 participants. The latest research, led by Dr. Lee Wheless, MD, PhD, an assistant professor at Vanderbilt University Medical Center and a staff physician at the VA Tennessee Valley Healthcare System, has dramatically expanded this evidence base. By analyzing a cohort of more than 33,000 veterans, the research team has provided a high-resolution look at how nicotinamide performs in a real-world, large-scale clinical setting.
The study, supported by a Department of Veterans Affairs grant, underscores a pivotal realization: nicotinamide is not merely a supplementary option for those with advanced skin cancer histories, but a powerful preventative tool that should ideally be deployed early in the progression of the disease. The data indicates an overall 14% reduction in skin cancer risk among users, but this figure tells only part of the story. For those who began the regimen after their first diagnosis, the risk of developing subsequent cancers plummeted by 54%.
Understanding Nicotinamide and the Mechanism of Action
Nicotinamide, also known as niacinamide, is a water-soluble form of vitamin B3 found in various foods and available as an inexpensive over-the-counter supplement. Unlike niacin, another form of B3, nicotinamide does not cause the "flushing" or skin redness that often discourages patients from adhering to a vitamin regimen.
The biological mechanism behind its effectiveness in skin cancer prevention is rooted in cellular energy and DNA repair. Ultraviolet (UV) radiation from the sun damages the DNA in skin cells and simultaneously depletes the cellular energy required to repair that damage. Specifically, UV radiation inhibits the production of adenosine triphosphate (ATP), the primary energy currency of the cell. Nicotinamide serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for ATP production. By replenishing these energy stores, nicotinamide enhances the skin’s natural ability to repair DNA damage caused by UV exposure and reduces the immunosuppressive effects of the sun, thereby preventing the mutations that lead to basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC).
The Methodology: Leveraging the VA Corporate Data Warehouse
One of the primary challenges in studying nicotinamide has been its status as an over-the-counter supplement. Because patients often purchase it outside of a clinical setting, it is rarely captured in traditional electronic medical records. To circumvent this data gap, Dr. Wheless and his colleagues turned to the Veterans Affairs Corporate Data Warehouse.
The VA system provides a unique research environment because it includes a comprehensive official formulary where nicotinamide is listed and prescribed by physicians. This allowed the researchers to track exactly who was taking the supplement, at what dosage, and for how long. The team reviewed the records of 33,833 veterans, focusing on those who received a baseline treatment of 500 milligrams of nicotinamide twice daily for a period exceeding 30 days.
This massive dataset allowed for a comparison between 12,287 patients who utilized nicotinamide and 21,479 who did not. The researchers tracked each patient’s subsequent diagnoses of BCC and SCC, the two most common forms of non-melanoma skin cancer, providing a clear statistical picture of the supplement’s impact over time.
Chronology of Evidence: From 2015 to the Present
The journey toward establishing nicotinamide as a standard of care has spanned nearly a decade:
- 2015: The ONTRAC Trial: The Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) study was published in the New England Journal of Medicine. It involved 386 participants and showed a 23% reduction in new non-melanoma skin cancers over 12 months. This established the "500mg twice daily" dosage as the clinical standard.
- 2016–2022: Incremental Adoption: Dermatologists began recommending the supplement to "high-risk" patients—typically those who had already suffered from five or more skin cancers. However, adoption was inconsistent due to the lack of large-scale, longitudinal data.
- 2023–2024: The VA Comprehensive Study: Dr. Wheless’s team utilized the VA’s vast records to provide the necessary scale. Their findings corroborated the 2015 trial but added critical nuance regarding the timing of intervention and the specific types of cancer most affected.
Analyzing the Data: Timing and Cancer Type
The study’s most striking revelation was the disparity in efficacy based on when the patient started the supplement. While the 14% overall risk reduction is statistically significant, the 54% reduction observed in patients who started nicotinamide after their very first skin cancer diagnosis suggests a "window of opportunity" for intervention.
As patients develop more skin cancers, the preventative benefit of nicotinamide appears to diminish. This is likely because the cumulative DNA damage in the skin reaches a threshold where metabolic support alone is insufficient to prevent new malignancies. This finding directly challenges current clinical habits, where doctors often wait until a patient is "burdened" by multiple cancers before suggesting a vitamin regimen.
Furthermore, the study found that the supplement was particularly effective against cutaneous squamous cell carcinoma (SCC). SCC is generally more aggressive than basal cell carcinoma and has a higher potential to metastasize if left untreated. The ability of a simple vitamin to significantly lower the risk of SCC represents a major public health opportunity, particularly for the aging veteran population.
Findings in Immunocompromised and Transplant Patients
The research team also examined a subset of 1,334 patients who were immunocompromised due to solid organ transplants. These patients are at an exponentially higher risk for skin cancer because the immunosuppressive drugs required to prevent organ rejection also hinder the body’s ability to surveil and destroy cancerous skin cells.
In this specific group, the overall risk reduction did not reach the level of statistical significance. However, the researchers did observe a link between early nicotinamide use and a lower incidence of SCC. This suggests that while nicotinamide is a valuable tool, it may not be a standalone solution for the most high-risk, immunocompromised populations, who may require more aggressive dermatological interventions.
Expert Reactions and Clinical Implications
"There are no guidelines for when to start treatment with nicotinamide for skin cancer prevention in the general population," noted Dr. Lee Wheless. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier."
The implications of this shift are profound. If nicotinamide is integrated into the standard care plan following a patient’s first non-melanoma skin cancer diagnosis, the healthcare system could see a substantial reduction in the number of surgical procedures required annually. Non-melanoma skin cancers are the most common cancers in the United States, with millions of cases diagnosed each year. The cost of treating these cancers—ranging from simple excisions to Mohs micrographic surgery—runs into the billions of dollars.
Dr. Wheless also emphasized the need for precision medicine in this area: "We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers." This comment highlights the next frontier of research: developing biomarkers or risk profiles to determine which patients are "progressors" who would benefit most from early nicotinamide intervention.
Broader Impact on Public Health
The VA study serves as a powerful reminder of the value of high-quality, real-world evidence. By using existing medical records to answer questions that would be too expensive or difficult to address through traditional clinical trials, the researchers have provided a roadmap for future preventative strategies.
For the general public, the message is clear: skin cancer prevention is not just about sunscreen and hats, although those remain essential. For those who have already had a skin cancer diagnosis, metabolic support through nicotinamide offers a secondary layer of defense that is safe, affordable, and highly effective if started early.
As dermatological societies review these findings, it is expected that clinical guidelines will be updated to reflect the importance of early intervention. This could lead to nicotinamide becoming a routine recommendation in the "post-op" consultation following a patient’s first successful skin cancer removal.
Conclusion and Future Outlook
The work of Dr. Wheless and his team, supported by the Department of Veterans Affairs and co-authored by a dedicated group at Vanderbilt—including Katyln Knox, Rachel Weiss, Siwei Zhang, Lydia Yao, Yaomin Xu, and Kyle Maas—marks a significant advancement in the fight against skin cancer. By proving that a common vitamin can cut the risk of subsequent cancers by more than half when used correctly, the study offers hope to millions of patients.
Future research will likely focus on the long-term effects of nicotinamide use over decades and whether it can be combined with other chemopreventative agents to further protect immunocompromised individuals. For now, the evidence points toward a simple, transformative change in medical practice: don’t wait for the second or third cancer to act—start the B3 today.
